Product Information
ARIPIPRAZOLE 30 MG TABLET is a generic product labeled by Major Pharmaceuticals, priced at $0.1843 per EA under NDC 00904737104. Its NADAC has been published 153 times since Dec 20, 2023.
FDA first approved this application on Jun 17, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
30 mg/1
Manufacturer
Major PharmaceuticalsNDC
00904737104
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
11/18/2026
Active Ingredients
ARIPIPRAZOLEApproval Type
Generic (ANDA)
FDA Application
ANDA204838FDA Approved
6/17/2016
TE Code
AB
On Market Since
6/20/2016
Pharmacological Classes
Price Statistics
The NADAC for ARIPIPRAZOLE 30 MG TABLET has been published 153 times since Dec 20, 2023, and over the history we have for it it has declined 27.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1843 per EA |
|---|---|
| All-time high | $0.2528 (Jan 10, 2024) |
| All-time low | $0.1365 (Nov 20, 2024) |
| 52-week high | $0.1843 |
| 52-week low | $0.1567 |
| Median price | $0.1750 |
| Average price | $0.1808 |
| Largest weekly change | +41.4% (Aug 21, 2024) |
| Weeks tracked | 153 |
| Tracking since | Dec 20, 2023 |
Generic Alternatives
The matcher finds 13 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 0% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Major Pharmaceuticals manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Aripiprazole market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Atypical Antipsychotic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ARIPIPRAZOLE 30 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ARIPIPRAZOLE 30 MG TABLET, manufactured by Major Pharmaceuticals, is $0.1843 per EA (NDC 00904737104), effective Nov 18, 2026.
How has the price of ARIPIPRAZOLE 30 MG TABLET changed over time?
Over the history we have for it, the NADAC for ARIPIPRAZOLE 30 MG TABLET has declined 27.1%. It has been tracked across 153 weekly CMS publications since Dec 20, 2023.
What are the highest and lowest recorded NADAC prices for ARIPIPRAZOLE 30 MG TABLET?
Since Dec 20, 2023, the NADAC for ARIPIPRAZOLE 30 MG TABLET has ranged from a low of $0.1365 (Nov 20, 2024) to a high of $0.2528 (Jan 10, 2024), with a median of $0.1750 per EA.
Are there cheaper alternatives to ARIPIPRAZOLE 30 MG TABLET?
Yes. 13 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ARIPIPRAZOLE 30 MG TABLET, is $0.1834 per EA — about 0% below ARIPIPRAZOLE 30 MG TABLET.
Who manufactures ARIPIPRAZOLE 30 MG TABLET?
ARIPIPRAZOLE 30 MG TABLET (NDC 00904737104) is labeled by Major Pharmaceuticals, and CMS classifies it as a generic product.